Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1

Conditions

Peritoneal Neoplasms 2Hyperthermia 2Carcinoma 2Pleural Effusion, Malignant 1Myeloproliferative Disorder, Chronic, with Eosinophilia 1Mesothelioma, Malignant 1Mesothelioma 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1Appendiceal Neoplasms 1Adrenocortical Carcinoma 1Abdominal Neoplasms 1

Interventions

Trastuzumab 2Docetaxel 2Carboplatin 2Bortezomib 2tipifarnib 1saracatinib 1Taxes 1Pleurodesis 1Paclitaxel 1Morphine 1LMB-100 1Interleukin-12 Subunit p35 1Interleukin-12 1Ibuprofen 1Gemcitabine 1Erlotinib Hydrochloride 1Decitabine 1Cytoreduction Surgical Procedures 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Pleural Effusion, Malignant × Cytoreduction Surgical Procedures × Clear all
NCT05375825 2024-02-02

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
MyeloidOther solid neoplasmThoracic

Myeloproliferative Disorder, Chronic, with Eosinophilia, Mesothelioma, Malignant, Carcinoma, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡